About Shire Canada
Shire is a global specialty biopharmaceutical company that works closely with
specialist physicians to develop and market medicines that improve the quality
of life for patients, their families and caregivers.
In Canada, Shire focuses on attention deficit hyperactivity disorder (ADHD),
human genetic therapies, as well as gastrointestinal and renal diseases.
Shire Canada is a market leader in providing effective therapies for ADHD,
one of the most common psychiatric disorders in children and adolescents. ADHD
is also increasingly recognized as a significantly undiagnosed conditions in the
adult population. Canadians living with ADHD, and their health care providers,
know the importance of medications like Shire's in helping them build healthy,
productive lives.
Shire Canada brings the same focus and dedication to gastrointestinal and
renal diseases. The company has pioneered a medication to enhance the treatment
of Canadians with end-stage renal disease that are undergoing dialysis. In the
gastrointestinal field, Shire has introduced to Canada a new treatment option
for patients living with ulcerative colitis, a type of inflammatory bowel
disease.
Shire Human Genetic Therapies (Canada) develops treatments for genetic
disorders known as rare or orphan diseases. Gaucher disease, Hunter syndrome
(MPS II) and Fabry disease are three examples of uncommon, extremely
debilitating medical diseases (lysosomal storage disorders) for which
Shire Human Genetic Therapies (Canada) is partnering with researchers
and specialist physicians to bring measurable improvements in health
as well as hope to patients and caregivers.
Shire Canada, in partnership with ViiV Healthcare, also provides
antiretroviral treatment options for persons in Canada living with HIV or
Hepatitis B.
Shire Canada and Shire Human Genetic Therapies (Canada) are wholly owned
subsidiaries of Shire plc.
Through the commitment of our employees, we are making a difference in the
health of Canadians and the communities in which they live.